Available at: Wilding JPH, Batterham RL, Davies M, et al
Increasing the dose too quickly, or taking more than the prescribed dose can increase the risk of side effects and cause harm to your health
1.2 Safety considerations and the limits of the GLP-1 analogy The success of GLP-1 receptor agonists should not obscure legitimate safety considerations associated with chronic peptide therapy
For perspective, here is every FDA-approved transdermal patch drug and its molecular weight
The agency notes that its not always possible to estimate the frequency of these reactions since they are voluntarily reported
Most are gastrointestinal, dose-dependent, more common early in titration, and tend to ease with continued treatment